Report of Foreign Issuer (6-k)
November 30 2017 - 4:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of November 2017
001-37353
(Commission
File Number)
BIONDVAX
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
14
Einstein St.
Ness
Ziona
Israel
74036
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
Financial Statements
for the period ending on September 30, 2017
On
November 28, 2017, BiondVax Pharmaceuticals Ltd. ("BiondVax") issued a press release announcing its financial results
for the period ended September 30, 2017. A copy of this press release and interim unaudited financial statements for period
ended September 30, 2017, are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein
by reference.
Appointment
of a new director
On November 27, 2017, our
board of directors appointed Dr. Morris C. Laster, M.D. as a director of the board.
Dr.
Laster possesses over 25 years of experience in the Biomed industry, with expertise in identification, evaluation, finance and
management of biomedical innovations in both public and private companies. Dr. Laster is a Venture Partner at OurCrowd a world
leading crowd funding platform and is the CEO of Clil Medical Ltd., a biomedical consultancy company. He is also the CEO of Vital
Spark Inc., a new company developing novel dual action cannabinoids licensed from the NIH. Previously, he served as the founding
CEO and director of BioLineRx Ltd. (NASDAQ/TASE: BLRX) from 2003 and until 2010. Dr. Laster is also one of the founders of Kitov
Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), and has served as a director in Kitov from 2010 and until 2014. Dr.
Laster holds an M.D. degree from SUNY Health Science Center At Brooklyn (SUNY HSCB) and B.S. in Biology, Magna Cum Laude, from
State University of New York at Albany.
Resolution
and Settlement in legal proceedings with consultant
On
May 29, 2014, we entered into a Consulting Services Agreement with a consultant. Pursuant to the Consulting Services Agreement
the consultant was granted 1,000,000 options exercisable for 1,000,000 of our ordinary shares. The consultant contended that pursuant
to this agreement, he was also entitled to 2.5% of the net proceeds received as a result of our initial public offering in May
2015. On March 2, 2015, we unilaterally cancelled this Consulting Services Agreement. As a result of the cancellation of the Consulting
Services Agreement all options previously granted to the consultant, vested or unvested, expired. On September 9, 2015, the consultant
brought a suit against us in the Israeli magistrate court in Tel Aviv, claiming that we wrongfully terminated the Consulting Services
Agreement and requesting monetary compensation in the amount of approximately NIS 1.5 million (approximately $380,000) and the
reinstatement of the previously cancelled options. On November 11, 2015, we filed our defense with the court wherein we contented
that the Consulting Services Agreement was lawfully cancelled and that the consultant’s suit has no legal basis.
Trial meetings were held
on September 25, 2017 and November 14, 2017. On November 26, 2017, the court approved a settlement of the legal proceedings according
to which, the Company agreed to pay Consultant a one time, mutually agreed and final payment in exchange for the final and complete
dismissal of the suit and all claims. BiondVax does not believe that this settlement payment will constitute a material financial
burden going forward.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax
Pharmaceuticals Ltd.
|
|
|
|
Date:
November 30, 2017
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron
Babecoff
|
|
|
Chief
Executive Officer
|
3
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024